*仅供医学专业人士阅读参考
最新资讯抢先看!
整理丨是橘不是桔
2024年美国临床肿瘤学会(ASCO)年会即将于美国时间5月31日至6月4日在芝加哥盛大召开。作为世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议之一,ASCO年会每年都汇集了众多世界一流的肿瘤学专家,和与会者们一起分享探讨当前国际最前沿的临床肿瘤学科研成果和肿瘤治疗技术,很多重要的研究发现和临床试验成果也会选择在ASCO年会上进行首次发布。
日前,ASCO年会摘要标题已公布,其中肺癌领域的重磅研究亮点不断!小编特此整理肺癌领域全体会议、口头摘要及快速口头摘要的部分重磅研究标题,供您参考!
图1 ASCO官网截图
全体大会专场:LAURA和ADRIATIC揭晓结果
■摘要号:LBA4
Osimertinib(osi)after definitive chemoradiotherapy(CRT)in patients(pts)with unresectable stage(stg)III epidermal growth factor receptor-mutated(EGFRm)NSCLC:Primary results of the phase 3 LAURA study
III期LAURA研究:在不可切除的III期表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC)患者中,奥希替尼作为最终CRT后续治疗方案的初步结果
汇报者:Suresh S. Ramalingam,美国埃默里大学医学院Winship癌症研究所
■摘要号:LBA5
ADRIATIC:durvalumab(D)as consolidation treatment(tx)for patients(pts)with limited-stage small-cell lung cancer(LS-SCLC)
ADRIATIC研究:度伐利尤单抗(D)作为局限期小细胞肺癌(LS-SCLC)患者(pts)巩固治疗方案(tx)的结果
汇报者:David R. Spigel,美国莎拉·坎农研究所
■摘要号:LBA3
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer
针对晚期肺癌患者使用远程医疗与面对面方式进行早期姑息治疗的疗效比较试验
汇报者:Joseph A. Greer,美国哈佛大学麻省总医院
口头摘要环节精彩不断,多项重磅研究成果即将公布
一、靶向篇:ADAURA、CROWN、ALINA等重磅研究数据更新,联合治疗探索不断
■摘要号:LBA8500
Sacituzumab govitecan(SG)vs docetaxel(doc)in patients(pts)with metastatic non-small cell lung cancer(mNSCLC)previously treated with platinum(PT)-based chemotherapy(chemo)and PD(L)-1inhibitors(IO):Primary results from the phase 3 EVOKE-01 study
III期EVOKE-01研究结果:戈沙托珠单抗(SG)与多西他赛(doc)治疗既往接受过铂类(PT)化疗(chemo)和PD(L)-1抑制剂(IO)治疗的转移性NSCLC患者
汇报者:Luis G. Paz-Ares,西班牙马德里
■摘要号:LBA8503
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer:5-year progression-free survival and safety from the CROWN study
CROWN研究5年无进展生存(PFS)率和安全性结果公布:比较洛拉替尼与克唑替尼在ALK+晚期NSCLC初治患者中的疗效与安全性
汇报者:Benjamin J. Solomon,澳大利亚彼得·麦卡勒姆癌症中心
■摘要号:LBA8505
Subcutaneous amivantamab vs intravenous amivantamab,both in combination with lazertinib,in refractory EGFR-mutated,advanced non-small cell lung cancer(NSCLC):Primary results,including overall survival(OS),from the global,phase 3,randomized controlled PALOMA-3 trial
全球、III期、随机对照PALOMA-3研究:Amivantamab皮下注射Vs Amivantamab静脉注射联合拉泽替尼治疗难治性EGFRm的晚期NSCLC的主要结果
汇报者:Natasha Leighl,加拿大玛格丽特公主癌症中心
■摘要号:8004
Adjuvant icotinib of 12 months or 6 months versus observation following adjuvant chemotherapy for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer(ICTAN,GASTO1002):A randomized phase 3 trial
一项随机III期试验(ICTAN,GASTO1 002):EGFRm II–IIIA期NSCLC患者接受12个月或6个月埃克替尼辅助治疗与辅助化疗后的观察
汇报者:王思愚教授,中山大学肿瘤防治中心
■摘要号:8005
Molecular residual disease(MRD)analysis from the ADAURA trial of adjuvant(adj)osimertinib in patients(pts)with resected EGFR‑mutated(EGFRm)stage IB–IIIA non-small cell lung cancer(NSCLC)
ADAURA试验:奥希替尼辅助治疗(adj)可切除的EGFRm IB-IIIA期NSCLC患者的微小残留病灶(MRD)分析
汇报者:Tom John,澳大利亚彼得•麦卡拉姆癌症研究中心
■摘要号:8006
Health-related quality of life(HRQoL)results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer(NSCLC):Data from ALINA
来自ALINA研究的数据:阿来替尼辅助治疗与化疗在可切除的ALK+ NSCLC患者中的健康相关生活质量(HRQoL)结果
汇报者:Makoto Nishio,日本癌研有明医院
■摘要号:8501
ICARUS-LUNG01:A phase 2 study of datopotomab deruxtecan(Dato-DXd)in patients with previously treated advanced non-small cell lung cancer(NSCLC),with sequential tissue biopsies and biomarkers analysis to predict treatment outcome
II期ICARUS-LUG01研究:通过连续组织活检和生物标志物分析预测Dato-DXd在经治的晚期NSCLC患者中的治疗结果
汇报者:David Planchard,法国古斯塔夫•鲁西肿瘤研究院
■摘要号:8504
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer(NSCLC)with biomarkers of high-risk disease:A secondary analysis from the phase 3 MARIPOSA study
III期MARIPOSA研究的二次分析结果:Amivantamab联合拉泽替尼与奥希替尼治疗具有高危疾病生物标志物的一线EGFRm晚期NSCLC患者
汇报者:Enriqueta Felip,西班牙Vall d'Hebron大学医院
■摘要号:8508
Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment(HARMONi-A):A randomized,double-blind,multi-center,phase 3 trial
随机、双盲、多中心、III期HARMONi-A研究:Ivonescimab联合化疗治疗接受EGFR酪氨酸激酶抑制剂(TKI)治疗进展后的EGFRm非鳞状NSCLC患者
汇报者:张力教授,中山大学肿瘤防治中心
二、免疫篇:中国研究亮相,新型药物群雄逐鹿
■摘要号:8001
BEAT-SC:A randomized phase III study of bevacizumab or placebo in combination with atezolizumab and platinum-based chemotherapy in patients with extensive-stage small cell lung cancer(ES-SCLC)
III期随机对照BEAT-SC研究:比较贝伐珠单抗或安慰剂联合阿替利珠单抗和铂类化疗治疗广泛期小细胞肺癌(ES-SCLC)患者的疗效与安全性
汇报者:Yuichiro Ohe,日本国立癌症研究中心
■摘要号:8008
A phase II randomized trial evaluating consolidative nivolumab in locally advanced non-small cell lung cancer post neoadjuvant chemotherapy plus nivolumab and concurrent chemoradiotherapy(GASTO-1091)
GASTO-1091研究:一项评估局部晚期NSCLC新辅助化疗+纳武利尤单抗和同步放化疗后纳武利尤单抗巩固治疗的II期随机试验
汇报者:刘慧教授,中山大学肿瘤防治中心
■摘要号:8502
Sacituzumab tirumotecan(SKB264/MK-2870)in combination with KL-A167(anti-PD-L1)as first-line treatment for patients with advanced NSCLC from the phase II OptiTROP-Lung01 study
II期OptiTROP-Lung01研究:SKB264/MK-2870联合KL-A167(抗PD-L1)作为晚期NSCLC患者的一线治疗方案
汇报者:方文峰教授,中山大学肿瘤防治中心
■摘要号:LBA8007
Clinical outcomes with perioperative nivolumab(NIVO)by nodal status among patients(pts)with stage III resectable NSCLC:Results from the phase 3 CheckMate 77T study
III期CheckMate77T研究:探索纳武利尤单抗(NIVO)围手术期治疗III期可切除NSCLC患者的淋巴结状态
汇报者:Tina undefined Cascone,Puerta de Hierro大学医院
三、其他研究
■摘要号:8009
Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer
针对重度吸烟者、有肺癌家族史的非吸烟者的地区肺癌早期检测计划
汇报者:Pan-Chyr Yang,国立台湾大学医学院
■摘要号:8506
NRG-LU002:Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy(LCT)plus maintenance systemic therapy for limited metastatic non-small cell lung cancer(NSCLC)
随机II/III期NRG-LU002研究:比较维持性全身治疗与局部巩固治疗(LCT)加维持性全身疗法治疗局部转移性NSCLC的结果
汇报者:Puneeth Iyengar,美国纪念斯隆凯特琳癌症中心
快速口头摘要“藏龙卧虎”!关键研究值得期待
■摘要号:8011
Outcomes with perioperative durvalumab(D)in pts with resectable NSCLC and baseline N2 lymph node involvement(N2 R-NSCLC):An exploratory subgroup analysis of AEGEAN
度伐利尤单抗围手术期治疗可切除NSCLC和基线N2淋巴结受累(N2R-NSCLC)患者中的结果:AEGEAN的探索性亚组分析
汇报者:John Heymach,MD安德森癌症中心
■摘要号:8012
Health-related quality of life(HRQoL)outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer(NSCLC)
随机、双盲3期KEYNOTE-671研究:帕博利珠单抗围手术期治疗患者的健康相关生活质量(HRQoL)结果
汇报者:Marina Chiara Garassino,美国芝加哥大学
■摘要号:8013
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors(TKI)to durvalumab(durva)or observation(obs)after chemoradiation(CRT)in unresectable locally-advanced ALK+ non-small cell lung cancer(NSCLC)
在不可切除的局部晚期ALK+ NSCLC中比较巩固ALK- TKI联合CRT后或巩固ALK- TKI联合度伐利尤单抗的观察性全球回顾性研究
汇报者:Ritujith Jayakrishnan,耶鲁大学纽黑文医院
■摘要号:8014
Overall survival of adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line treatment for extensive-stage small cell lung cancer.
Adebrelimab联合化疗和序贯胸腔放疗作为ES-SCLC一线治疗的总生存期
汇报者:Dawei Chen,山东省肿瘤医院
■摘要号:8015
DeLLphi-301:Tarlatamab phase 2 trial in small cell lung cancer(SCLC)—Efficacy and safety analyzed by presence of brain metastasis.
II期DeLLphi-301研究:通过脑转移分析Tarlatamab治疗SCLC的疗效和安全性
汇报者:Anne-Marie C. Dingemans,荷兰伊拉斯姆斯医学中心
■摘要号:8018
ctDNA-Lung-DETECT:ctDNA outcomes for resected early stage non-small cell lung cancers at 12 months
ctDNA-Lung-DETECT研究:探索12个月时接受手术切除的早期NSCLC患者的ctDNA
汇报者:Sam Khan,加拿大玛格丽特公主癌症中心
■摘要号:8513
A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations:Primary analysis of WU-KONG1 study.
舒沃替尼治疗含铂化疗失败的EGFR 20号外显子插入突变NSCLC的一项国际多中心注册临床研究:WU-KONG1的初步分析结果
汇报者:杨志新教授,台湾大学肿瘤中心医院
■摘要号:8514
Phase Ia/Ib trial of zongertinib(BI 1810631), a HER2-specific tyrosine kinase inhibitor(TKI), in patients(pts)with HER2 aberration-positive solid tumors:Updated Phase Ia data from Beamion LUNG-1, including progression-free survival(PFS)data.
HER2特异性TKI zongertinib(BI1810631)治疗HER2畸变阳性实体瘤患者的Ia/Ib期试验:来自BeamionLUNG-1的最新Ia期数据(包括PFS数据)
汇报者:John Heymach,MD安德森癌症中心
■摘要号:8515
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
II期开放标签、单臂RAGNAR研究:探索厄达替尼在NSCLC和预先指定的成纤维细胞生长因子受体改变的成人中的疗效和安全性
汇报者:Martin H. Schuler,德国埃森大学医学院
■摘要号:8516
Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer(NSCLC):Results from CHRYSALIS-2.
CHRYSALIS-2研究结果:Amivantamab联合拉泽替尼治疗非典型EGFRm晚期NSCLC
汇报者:Byoung Chul Cho,韩国延世大学医学院
■摘要号:8517
A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease.
Amivantamab联合拉泽替尼治疗EGFRm肺癌和活动性中枢神经系统疾病的II期研究
汇报者:Helena Alexandra Yu,美国纪念斯隆凯特琳癌症中心
■摘要号:8518
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation(SABR)in advanced EGFR mutant non-small cell lung cancer(NSCLC):Results from a multi-center phase II trial.
奥希替尼联合巩固立体定向消融放疗(SABR)治疗晚期EGFRm NSCLC的安全性和有效性:一项多中心II期试验的结果
汇报者:Sawsan Rashdan,美国德克萨斯州立大学
■摘要号:8519
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer:A multicenter, open-label, single-arm, phase 2 trial.
洛拉替尼治疗TKI初治晚期ROS1+ NSCLC:一项多中心、开放标签、单臂II期试验
汇报者:Beung Chul AHN,韩国国立癌症中心
■摘要号:8520
Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer:The phase 2 TRUST-I study.
II期TRUST-I研究:Taletrectinib在晚期或转移性ROS1+ NSCLC中的疗效和安全性
汇报者:李玮教授,上海市肺科医院
■摘要号:8521
Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC:Updated phase 1 results(SGNB6A-001).
SGNB6A-001研究I期结果更新:ADC sigvotatug vedotin在NSCLC中的疗效和安全性
汇报者:Solange Peters,瑞士沃杜瓦大学中心医院
■摘要号:LBA8010
Neoadjuvant nivolumab(NIVO)+ chemotherapy(chemo)vs chemo in patients(pts)with resectable NSCLC:4-year update from CheckMate 816.
CheckMate 816研究4年数据更新:比较新辅助纳武利尤单抗联合化疗与化疗治疗可切除NSCLC的最新结果
汇报者:Jonathan Spicer,加拿大麦吉尔大学
精彩资讯等你来
责任编辑:Sheep
*医学界力求其发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.